An overexpressed N-ras proto-oncogene cooperates with N-methylnitrosourea in mouse mammary carcinogenesis

R Mangues1, J M Kahn, I Seidman

  • 1Department of Pathology, New York University Medical Center, New York 10016.

Cancer Research
|December 15, 1994
PubMed

Insights

Overexpression of the N-ras proto-oncogene accelerates mammary tumor development in mice treated with N-methylnitrosourea (MNU). This overexpression cooperates with MNU-induced mutations in other genes, highlighting a novel pathway in carcinogenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Carcinogenesis Research

Background:

  • Oncogene involvement in carcinogenesis is studied using chemical tumor induction and transgenic animal models.
  • N-ras proto-oncogene overexpression is linked to mammary tumors and lymphomas in transgenic mice.
  • Understanding oncogene cooperation with carcinogens provides insights into tumor development.

Purpose of the Study:

  • To investigate the cooperative effect of N-methylnitrosourea (MNU) treatment and N-ras proto-oncogene overexpression in tumorigenesis.
  • To analyze tumor incidence, latency, transgene expression, and ras gene mutations in response to MNU in transgenic mice.

Main Methods:

  • Transgenic mice overexpressing the N-ras proto-oncogene were treated with N-methylnitrosourea (MNU) or a control.
  • Tumor incidence and latency were monitored for mammary tumors and lymphomas.
  • Levels of transgene expression and patterns of ras mutations (H-, K-, and N-ras codons 12, 13, 61) were analyzed in tumors.

Main Results:

  • MNU treatment significantly shortened the latency of mammary tumors in N-ras overexpressing mice compared to controls.
  • All mammary tumors showed N-ras transgene overexpression and lacked ras mutations.
  • N-ras overexpression did not cooperate with MNU in lymphomagenesis; lymphomas showed varied ras mutation patterns.

Conclusions:

  • N-ras proto-oncogene overexpression cooperates with non-ras genes mutated by MNU in mouse mammary carcinogenesis.
  • Proto-oncogene overexpression represents an alternative mechanism for ras pathway activation, distinct from point mutations.
  • The findings suggest N-ras overexpression may play a role in human breast tumorigenesis, warranting further investigation.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...